Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer.
Roni Nitecki WilkeAlexandra S BercowAllison A GockleyHang LeeRichard T PensonWhitfield B GrowdonPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
In patients with ovarian cancer, clinical trial enrollment is associated with chemotherapy administration within 14 days of death, but not other measures of aggressive care at the end of life. Given the importance of clinical trial participation in improving care for women with ovarian cancer, this study suggests that concerns regarding aggressive care prior to death should not limit clinical trial participation.